Genetic Technologies and BioVie Interviews to Air on the RedChip...

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVRedChip Companies will air interviews with Genetic Technologies (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Genetic Technologies is focusing on commercializing its geneType multi-risk test, while BioVie is developing therapies for neurodegeneration and liver disea
Access the interviews in their entirety at:

Genetic Technologies: https://www.redchip.com/assets/access/gene_access

BioVie: https://www.redchip.com/assets/access/bivi_access

In an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corporate update. Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease and Type-2 diabetes, a first-in-class test that can predict a person's risk in up to 70% of annual mortalities and morbidities before onset. The Multi-Risk test, along with integration of recently acquired DNA based products, underpin a broad and complementary portfolio of genomic based tests creating a significant competitive advantage. GENE's expanding product portfolio includes more than 50 risk assessment tests in 14 test categories covered by 25 patents granted and nine patents pending. In addition to its B2B model, GENE is also focused on expanding its direct-to-consumer testing programs. The global market for predictive genomics is expected to reach $4.6 billion by 2025, growing at a CAGR of 17%+.

Cuong Do, President and CEO of BioVie, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corporate update. BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer's (AD) and Parkinson's (PD) and BIV201 for refractory ascites and HRS-AKI. BioVio recently reported data from a Phase 3 trial in AD that showed positive trending data showing that patients treated with NE3107 had treatment advantages compared to placebo on various cognitive, functional, and biomarker endpoints. The Company plans to launch Phase 3 trials in Alzheimer's, Parkinson's, and Ascites in 2024 and has multiple other efforts underway that may create additional catalysts.